Mast Therapeutics Inc  

(Public, NYSEMKT:MSTX)   Watch this stock  
Find more results for AMEX:ANX
0.472
-0.009 (-1.87%)
Apr 17 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.47 - 0.50
52 week 0.40 - 0.73
Open 0.50
Vol / Avg. 540,945.00/880,548.00
Mkt cap 75.26M
P/E     -
Div/yield     -
EPS -0.24
Shares 159.46M
Beta 2.60
Inst. own 31%
May 4, 2015
Q1 2015 Mast Therapeutics Inc Earnings Release (Estimated) Add to calendar
Mar 24, 2015
Q4 2014 Mast Therapeutics Inc Earnings Release
Mar 2, 2015
Mast Therapeutics Inc at Cowen Health Care Conference - Webcast
Feb 9, 2015
Mast Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 9, 2015
Mast Therapeutics Inc at 17th Annual BIO CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -46.32% -45.65%
Return on average equity -56.46% -53.92%
Employees 23 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 500
SAN DIEGO, CA 92130-3324
United States - Map
+1-858-5520866 (Phone)
+1-858-5520876 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Mast Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188, the Company�s lead product candidate. MST-188 has demonstrated multiple pharmacologic effects that provide clinical benefit in a range of diseases and conditions characterized by impaired microvascular blood flow and damaged cell membranes. MST-188 has orphan drug status for the treatment of sickle cell disease in the U.S. and European Union. The Company�s pipeline includes MST-188 development programs in adjunctive thrombolytic therapy, such as acute limb ischemia, stroke; heart failure, and resuscitation following trauma, such as restoration of circulating blood volume and pressure. The product is in Phase 2a of its clinical trial.

Officers and directors

Jack Lief Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Brian M. Culley Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Brandi L. Roberts C.P.A Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Principal Financial Officer
Age: 40
Bio & Compensation  - Reuters
R. Martin Emanuele Ph.D Senior Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Gregory D. Gorgas Senior Vice President - Commercial
Age: 51
Bio & Compensation  - Reuters
Edwin L. Parsley D.O. Chief Medical Officer & Senior Vice President
Bio & Compensation  - Reuters
Howard C. Dittrich M.D. Independent Director
Bio & Compensation  - Reuters
David A. Ramsay CPA Independent Director
Age: 50
Bio & Compensation  - Reuters
Lewis J. Shuster Independent Director
Bio & Compensation  - Reuters